DHQZ-17

DHQZ-17 is a small molecule inhibitor characterized as a potent and selective inhibitor of the transcription factor **Hepatocyte nuclear factor 4 alpha (HNF4A)**. It has demonstrated the ability to suppress tumorigenicity in head and neck squamous cell carcinoma (HNSCC) models, showing strong antiproliferative effects with low toxicity to normal cells[1][3][4][7]. The compound is part of a structural class known as dihydroquinazolinones and was developed through structure-activity relationship screens for anticancer activity targeting transcriptional regulators. Its primary mechanism is believed to involve inhibition of HNF4A-mediated transcription, disrupting key tumorigenic signaling pathways in affected cells[1][3][4][7].